In this issue:
Treatment decision tool for stage III colon cancer
mFOLFOX6 + bevacizumab for liver metastases
FOLFOXIRI + bevacizumab improves OS in mCRC
Surveillance for colorectal peritoneal metastases
Prolonged OS with dual checkpoint inhibition in refractory CRC
Carboplatin + paclitaxel for advanced anal cancer
Prognostic power of the Pan-Immune-Inflammation Value in mCRC
Modest activity of ensituximab in refractory CRC
Predictive value of primary tumour location in mCRC
CRC incidence and mortality after polypectomy
Please login below to download this issue (PDF)